Angelica Peebles

The FDA's investigation into the source of the cyclosporiasis outbreak is causing confusion as companies and consumers alike navigate new updates.

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

Anthropic will start an internal drug discovery program, part of a new push to sell artificial intelligence tools to drugmakers.

Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.

Estrogen patches are in short supply as demand for menopause treatments skyrockets, and it could take at least a year for manufacturers to catch up.

CNBC’s Angelica Peebles reports on the latest news.

The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.

At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the July 1 start date of GLP-1 coverage for seniors on Medicare.